Two Phase 3 Trials of Baricitinib for Alopecia Areata
May 2022
in “The New England Journal of Medicine”
TLDR Baricitinib was effective in treating alopecia areata in two major trials.
We don't know much about this study yet.
We're maintaining the world's largest resposity of hair loss research. You can help out the community by sending a PDF of this study here . Not sure how to get a study's PDF? You can email the authors of the study.Cited in this study
research Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
Baricitinib is effective and safe for treating severe alopecia areata.
research “‘You lose your hair, what’s the big deal?’ I was so embarrassed, I was so self-conscious, I was so depressed:” a qualitative interview study to understand the psychosocial burden of alopecia areata
Alopecia Areata (AA) causes significant emotional distress, including feelings of embarrassment, depression, and anxiety, and impacts social interactions and daily activities.
research Treatment of severe alopecia areata with baricitinib
Baricitinib helped a woman with severe hair loss regrow almost all her hair without side effects.
research The role of Janus kinase inhibitors in the treatment of alopecia areata: A systematic review
Janus kinase inhibitors show promise for treating alopecia areata but need more research for confirmation.
research JAK inhibitors for alopecia areata: a systematic review and meta‐analysis
JAK inhibitors are effective for treating alopecia areata, with most patients seeing hair growth after treatment.
research Treatment of alopecia areata: An Australian expert consensus statement
research JAK Inhibitors for Treatment of Alopecia Areata
JAK inhibitors can effectively reverse hair loss in people with alopecia areata.
research An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
Tofacitinib may help treat severe hair loss, but more research is needed.
research Alopecia areata
Some treatments can help with a hair loss condition called alopecia areata, but none ensure lasting results; choices depend on the person, with JAK inhibitors showing promise for severe cases.
research JAK inhibitors in dermatology: The promise of a new drug class
JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.
research Health-related quality of life (HRQoL) among patients with alopecia areata (AA): A systematic review
People with alopecia areata, a skin disease, generally have a poor quality of life, especially if more of their scalp is affected.
research Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
research Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata
Ruxolitinib effectively regrows hair in most patients with severe hair loss.
research Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.
research Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.
research S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents
Guidelines for diagnosing common hair loss include detailed history, clinical examination, and various diagnostic techniques.
Related
research Baricitinib Results in Eyebrow and Eyelash Growth in Patients With Alopecia Areata Who Do Not Achieve 20% or Less Scalp Hair Loss
Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.
research Sensitive scalp: An epidemiologic study in patients with hair loss
Many people with hair loss, especially those with telogen effluvium and alopecia areata, often have a sensitive scalp.
research Time to loss of response for dupilumab in ophiasis-pattern alopecia areata
Dupilumab helped a woman with severe hair loss regrow her hair quickly and maintain it for six months after stopping treatment.
research A clinico-epidemiological study of scalp hair loss in children (0–18 years) in Kota Region, South-East Rajasthan
About 12% of children in Kota, Rajasthan, experience hair loss, mainly due to fungal infections, with early treatment advised to prevent worsening.
research Topical and intralesional therapies for alopecia areata
No treatments fully cure or prevent alopecia areata; some help but have side effects or need more research.
research Alopecia areata: Clinical presentation, diagnosis, and unusual cases
Alopecia areata is a type of hair loss that can lead to complete baldness, often associated with other autoimmune conditions, and half of the cases may see hair return within a year.